Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine versus lopinavir/ritonavir for mild to moderate COVID-19
ChiCTR2000029741Phase 4Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of chloroquine and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Length of stay, Time to severe disease and 9 more. Started Feb 2020; status: recruiting.
02
Drugs
chloroquinelopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029741.